MD20200027A2 - Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor - Google Patents

Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor Download PDF

Info

Publication number
MD20200027A2
MD20200027A2 MDA20200027A MD20200027A MD20200027A2 MD 20200027 A2 MD20200027 A2 MD 20200027A2 MD A20200027 A MDA20200027 A MD A20200027A MD 20200027 A MD20200027 A MD 20200027A MD 20200027 A2 MD20200027 A2 MD 20200027A2
Authority
MD
Moldova
Prior art keywords
treatment
diseases associated
compound
pharmaceutically acceptable
well
Prior art date
Application number
MDA20200027A
Other languages
English (en)
Russian (ru)
Other versions
MD4788C1 (ro
MD4788B1 (ro
Inventor
Владимир НЕБОЛЬСИН
Анастасия РЫДЛОВСКАЯ
Original Assignee
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” filed Critical OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
Publication of MD20200027A2 publication Critical patent/MD20200027A2/ro
Publication of MD4788B1 publication Critical patent/MD4788B1/ro
Publication of MD4788C1 publication Critical patent/MD4788C1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invenţia se referă la medicină, în particular, la terapia afecţiunilor, asociate cu activitatea aberantă a fractalkinei şi a proteinelor chemoatractante monocitare 1-4 (CCL2, CCL7, CCL8, CCL13), preponderent, la terapia sindromului algic, febrei, pneumoniei, bronşitei, bronşiolitei, alveolitei, artritei reumatoide şi psoriazisului, precum şi altor boli, utilizând compusul 1-(2-(1H-imidazol-4-il)etil)piperidin-2,6-dioneisau sarea acceptabilă farmaceutic sau solvatul acestuia.Prezenta invenţie se referă, de asemenea, la compoziţii farmaceutice, care conţin o cantitate eficientă terapeutic de compus, conform invenţiei. Compusul dat, precum şi sărurile sale acceptabile farmaceutic, posedă o eficienţă înaltă în inhibarea activităţii enzimei glutaminilciclază, implicate, în particular, în procesele de modificare post-translaţională a citokinelor menţionate.
MDA20200027A 2017-09-07 2018-03-06 Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor MD4788C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017131435 2017-09-07
PCT/RU2018/000135 WO2019050429A1 (ru) 2017-09-07 2018-03-06 Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов

Publications (3)

Publication Number Publication Date
MD20200027A2 true MD20200027A2 (ro) 2020-09-30
MD4788B1 MD4788B1 (ro) 2022-02-28
MD4788C1 MD4788C1 (ro) 2022-09-30

Family

ID=65634221

Family Applications (2)

Application Number Title Priority Date Filing Date
MDA20210031A MD4802C1 (ro) 2017-09-07 2018-03-06 Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
MDA20200027A MD4788C1 (ro) 2017-09-07 2018-03-06 Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MDA20210031A MD4802C1 (ro) 2017-09-07 2018-03-06 Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor

Country Status (9)

Country Link
US (1) US11439631B2 (ro)
CN (1) CN111093661B (ro)
CL (1) CL2020000554A1 (ro)
EA (2) EA039391B1 (ro)
GE (4) GEP20227402B (ro)
MD (2) MD4802C1 (ro)
MY (1) MY197850A (ro)
PH (1) PH12020500462A1 (ro)
WO (1) WO2019050429A1 (ro)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
WO2021262040A1 (ru) * 2020-06-26 2021-12-30 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524157D0 (en) * 1995-11-25 1996-01-24 Pfizer Ltd Therapeutic agents
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
MX2007016290A (es) * 2005-06-30 2008-03-10 Celgene Corp Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona.
GB201009603D0 (en) * 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
US20160046898A1 (en) * 2014-08-12 2016-02-18 Pbs Biotech, Inc. Cell growth macrocarriers for bioreactors

Also Published As

Publication number Publication date
MD4802C1 (ro) 2022-11-30
MD4788C1 (ro) 2022-09-30
WO2019050429A1 (ru) 2019-03-14
GEAP202215309A (en) 2022-04-11
CN111093661A (zh) 2020-05-01
EA201992341A8 (ru) 2020-08-11
CL2020000554A1 (es) 2020-10-23
US11439631B2 (en) 2022-09-13
EA039391B1 (ru) 2022-01-21
MY197850A (en) 2023-07-20
GEP20227402B (en) 2022-08-10
GEP20227354B (en) 2022-02-25
US20200188379A1 (en) 2020-06-18
MD20210031A2 (ro) 2021-10-31
CN111093661B (zh) 2023-10-27
MD4802B1 (ro) 2022-04-30
PH12020500462A1 (en) 2021-01-11
EA201992341A1 (ru) 2020-02-28
GEAP202115467A (en) 2021-10-11
EA201992337A1 (ru) 2020-02-13
MD4788B1 (ro) 2022-02-28

Similar Documents

Publication Publication Date Title
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
CR20200263A (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
WO2016085221A3 (ko) 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
MD20210031A2 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EP4631505A3 (en) Crystalline forms and salt forms of a kinase inhibitor
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
MX2024011914A (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
WO2025019309A3 (en) Compounds and compositions as c-kit kinase inhibitors
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202190452A1 (ru) Ингибиторы cdk8/19
MX2023005071A (es) Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas.
MD4844B1 (ro) Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
MX2024001441A (es) Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.

Legal Events

Date Code Title Description
PD4A Change of proprietorship (patent for invention)

Owner name: LTD VALENTA-INTELLEKT, RU UL. RYABINOVAYA, D. 26 BUILDING 10, CAB. 6-26, MOSCOW, 121471, FEDERATIA RUSA;IP NEBOLSIN VLADIMIR EVGHENIEVICH, RU STR. GOLITSYNSKAYA, 457, ISTRINSKIY R-N, D. BORZYE, MOSKOVSKAYA OBL., 143581, FEDERATIA RUSA

Free format text: PREVIOUS PROPRIETOR: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES",RU 121205, MOSCOW, MOZHAISKY MUNICIPAL DISTRICT, TERRITORY OF THE SKOLKOVO INNOVATION CENTER, BOLSHOY BOULEVARD, HOUSE 42, BUILDING 1, FLOOR 3, ROOM 1280, FEDERATIA RUSA

FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
NF4A Restoration of lapsed patent for invention